NEWS

April 2026

MediKane Media Release 28 April 2026

MediKane is looking to raise investment funds through its own network, and also through the BizDealRoom.

Below is the current summary of the business.

Company Background

MediKane Holdings Ltd is a natural product healthcare company founded in 2010, focused on transforming the management of chronic health conditions through clinically validated, science-backed nutrition. MediKane enables consumers to proactively manage their health, shifting the focus from reactive treatment to preventive care. Over the past decade, we have conducted extensive research and development, resulting in clinically proven products branded NutriKane, and positioned to meet the growing demand for preventative health solutions for specific chronic health conditions.

Products / Services Offered

At the core of our offerings is NutriKane, a range of clinically validated nutritional products designed for the prevention and management of chronic health issues, such as diabetes, bowel health, and inflammation. Our proprietary processing technology ensures high-performance health outcomes, making our products a trusted choice among healthcare professionals and patients alike. Each product in our portfolio is tailored to meet specific health needs, backed by rigorous clinical trials and positive patient outcomes.

Target Market and Customer Base

Our primary target demographic consists of health-conscious adults aged 35 to 65 who are increasingly focusing on preventive health solutions. This audience is not only informed about the benefits of natural products but is also motivated by a desire for efficacy and scientific backing. The purchasing behaviour of our customers is characterised by exceptional brand loyalty, driven by proven results and endorsements from healthcare practitioners.

Competitive Advantages

MediKane stands out in the natural health market due to our strong clinical validation, proprietary processing technology, and vertically integrated supply chain of high-quality Australian ingredients. Our products have been tested rigorously in clinical environments, providing a level of credibility that is rare in the industry. This not only positions us favourably against competitors but also creates barriers to entry for other brands.

Achievements

In the past decade, we have built a strong track record, including multiple successful clinical trials that validate our product effectiveness. We have established a stable base of repeat customers and strategic partnerships for distribution in high-demand markets, such as the Philippines and China, demonstrating our readiness for international expansion.

Current Traction

As current shareholders know, MediKane revenue stopped growing about 5 years ago when a key supplier failed, meaning MediKane could not produce enough NutriKane.

That situation was since rectified with the establishment of a tied supplier that began commercial operations late 2025. The new supplier is well managed and its technology delivers a technically superior ingredient in terms of health efficacy and the extended range of nutrients it now supplies MediKane.

With certainly of ingredient supply, MediKane is now supplying agents in Australia, China and the Philippines.

The new ‘Go to Market’ approach is based on many years of experience both internally and with others. It is available to serious investors.

Future Goals

Our intention is to scale the company through aggressive marketing strategies and the launch of new product lines targeting significant market segments such as brain health and preventive nutrition. We project substantial growth as we enter the international market, particularly in Asia, and aim for a high-multiple exit by 2027 through a trade sale or IPO, maximising shareholder value

For those, interested please call MediKane or send an email to (info@medikane.com.au)

The link for BizDealroom is: BizDealRoom | The Complete Capital Raising Platform

Note that existing shareholders can qualify for a 10% lower share price.

Conditions Apply.

Updated: January 2026

The Health Problem We Address

Chronic diseases represent one of the fastest-growing health challenges globally. Increasing evidence now links gut health and nutrition to the prevention, management and potential reversal of many chronic conditions.

Consumers are actively seeking:

·       Natural, food-based health solutions

·       Products with credible scientific backing

·       Safe options that can be used alongside conventional treatments

This demand now extends beyond digestive health to include metabolic health, inflammation and cognitive decline, including dementia.

The MediKane Solution

MediKane develops Food as Medicine products that deliver therapeutic nutrition in clinically appropriate dosages.

Key characteristics:

·       Food-registered (not supplements)

·       Scientifically formulated and tested

·       Supported by over 13 years of research

·       Independent validation through institutions including Royal Melbourne Hospital and Macquarie University

·       Designed to deliver measurable outcomes quickly

·       No known side effects

MediKane products are intended to complement pharmaceutical and lifestyle therapies, not replace them.

Scientific & Competitive Advantage

MediKane’s differentiation lies in formulation science, ingredient quality and clinical intent.

·       Unique fibre-based ingredients and proprietary formulations

·       High efficacy outcomes across a broad user base

·       Can be used safely alongside prescription medications

·       Positioned as nutrition therapy rather than general supplementation

Unlike many gut health supplements, MediKane products are designed for functional outcomes, not wellness positioning alone.

Market Landscape

MediKane operates within the Natural Health Products and Nutraceuticals sector.

·       The global natural health market was valued at USD 85 billion in 2025, with strong long-term growth driven by plant-based, clean-label and science-backed solutions.

·       The digestive and gut health category alone was valued at USD 18.4 billion in 2024, reflecting growing consumer awareness of the gut’s role in whole-body health.

Growth drivers include:

·       An ageing population

·       Rising prevalence of chronic disease

·       Increased consumer demand for preventative health solutions

Target Customers

Primary customers include:

·       Women aged 35–65+ seeking to age well and extend healthspan

·       Individuals managing or seeking to prevent chronic conditions, particularly:

o   Diabetes

o   Gut and bowel disorders

o   Cognitive health decline

Secondary customers include healthcare practitioners and institutional settings.

Routes to Market

MediKane operates a diversified distribution model, including:

·       Direct-to-consumer (online)

·       Health food stores and pharmacies

·       Healthcare and medical channels (including hospitals and aged care)

·       White-label partnerships (human and pet applications)

·       International distribution, including Asia-Pacific markets

This multi-channel approach reduces dependency on any single route to market.

Traction & Operating History

·       Over 12 years of operating experience

·       Proven repeat purchase behaviour driven by efficacy and product acceptance

·       Established domestic and international distribution experience

·       Demonstrated ability to operate through:

o   Supply chain disruption

o   The COVID-19 pandemic

o   Capital-constrained environments

MediKane has refined its operating model while maintaining product integrity and customer loyalty.

Intellectual Property & Defensibility

MediKane’s position is protected through a combination of formal IP and proprietary know-how:

·       Application patents at PCT stage (including Diabetes and Coeliac Disease)

·       Additional patents in preparation across:

o   Auto-immune disease

o   Inflammation

o   Women’s and pregnancy health

·       Trade secrets and formulation know-how

·       Registered trademarks and brand assets

Why MediKane, Why Now

Several structural and market shifts align strongly with MediKane’s platform:

·       Ageing populations seeking longevity-focused health solutions

·       Increased awareness of gut health’s role in metabolic and cognitive conditions

·       Rising interest in nutrition support alongside GLP-1 therapies

·       Improved supply chain following transition to a high-quality, sustainable fibre supplier

·       Accelerating demand for simple, effective, clinically grounded gut health products

MediKane is now positioned to scale with the right capital and execution support.

Investment Snapshot

·       Unlisted Australian public company

·       No institutional investors currently on the cap table

·       Clean capital structure

·       Clear pathway for growth and strategic exit

·       Opportunities for active investor involvement, including board participation

Indicative investment terms are available on request.